INSMED Inc

This biopharmaceutical company focuses on discovering, developing, and commercializing novel therapies for serious respiratory, immunological, inflammatory, and rare diseases. Its commercial portfolio features two approved products: ARIKAYCE, an inhaled liposomal antibacterial treatment for refractory Mycobacterium avium complex lung infections, and BRINSUPRI, an oral daily tablet indicated for non-cystic fibrosis bronchiectasis. The company also advances a clinical pipeline that includes TPIP, an inhaled dry-powder prodrug formulation targeting pulmonary arterial hypertension and related interstitial lung disorders, alongside gene therapy candidates for rare conditions such as Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its primary end customers are adult and adolescent patients experiencing severe, chronic, and debilitating diseases with limited existing treatment alternatives.

The enterprise maintains an international operating scale, securing regulatory clearances and distributing treatments across North America, Europe, and Asia. Its therapies have achieved commercial approvals and distribution across the United States, Japan, the United Kingdom, and European Union member nations including France, Germany, Italy, Spain, Belgium, the Netherlands, and Ireland. The company's global clinical development programs encompass operations spanning hundreds of trial sites across dozens of countries. The excerpt does not disclose the location of the corporate headquarters.

Summary of the business section of Insmed's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had a total of 1,664 full-time employees: 736 in research, clinical, regulatory, medical affairs and quality assurance; 107 in technical operations, manufacturing and quality control; 266 in general and administrative functions; and 555 in commercial activities.”